JPRN-UMIN000020956已完成未知
Evaluation of effect of pyridoxamine on reducing carbonyl stress in patients receiving peritoneal dialysis. -Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis - - Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients receiving hemodialysis in addition to peritoneal dialysis. 2. Patients with severe liver disease or liver dysfunction (AST, ALT >ULN X1.25) 3. Patients with history of allergy (anaphylactic shock, drug eruption) or severe adverse effects to certain drugs. 4. Patients who use medications containing vitamin B6 or are not able to stop the medications. 5. Patients participating in other clinical trial or received investigational products in the last 16 weeks. 6. Patients having active cancers or received complete resection of cancers in the last 3 years. 7. Patients with history of cardiovascular disease in the last 6 months. 8. Patients receiving peritoneal dialysis for more than 8 years or having suspected encapsulating peritoneal sclerosis. 9. Patients with peripheral arterial disease which is more than Fontaine stageII. 10. Patients with uncontrolled hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 120mmHg) under combination treatment of antihypertensive drugs. 11. Patients with uncontrolled diabetes (HbA1c>8.0%). 12. Patients with anemia (Hb<9g/dl) in which erythropoietin is not effective. 13. Patients received prohibited combined drugs described below in the last 4 weeks. Aminophylline, theophylline, choline, theophylline, levodopa, pyridoxal, pyridoxine, etc. 14. Pregnant women or those intending to become pregnant during the next 1 year. 15. Patients judged as inappropriate candidates for the trial by the principal investigator or the sub-investigators.
研究者
相似试验
招募中
2 期
Pyridoxamine for menopausal disordermenopausal disorder with psychological symptomsJPRN-jRCTs031220256Terauchi Masakazu50
招募中
不适用
The effect of pyridoxamine supplementation on microvascular function in type 2 diabetes: a double-blind randomized placebo-controlled cross-over trialNL-OMON56635niversiteit Maastricht40
招募中
不适用
The effect of pyridoxamine supplementation on vascular function and insulin sensitivity; a double-blind randomized placebo controlled trial in abdominally obese subjects.Insulin resistance1001842410003216obesityNL-OMON50192niversiteit Maastricht172
已完成
2 期
The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase 2 trialAutism Spectrum DisorderJPRN-jRCT2021200001Kure Shigeo78
已完成
2 期
The efficacy and safety of pyridoxamine in patients with autism spectrum disorder; Exploratory physician-led Phase II trialAutism spectrum disorderJPRN-UMIN000035172Department of Pediatrics,Tohoku University Hospital72